Exercise of SAYE Options and PDMR Dealing

RNS Number : 2763M

CVS Group plc

10 January 2023

 

10 January 2023

CVS Group Plc

("CVS" or the "Company")

Exercise of SAYE Options, PDMR Dealing

and Total Voting Rights

CVS, one of the UK's leading providers of integrated veterinary services, announces that on 10 January 2023, options over a total of 106,955 ordinary shares of 0.2 pence each (the "Ordinary Shares") were exercised under the CVS Group 2019 SAYE Plan (2019/2023), at an exercise price of £8.63.  Additionally, deferred options over a total of 1,474 Ordinary Shares were exercised under the CVS Group 2018 SAYE Plan (2018/2022) taking the total options exercised on 10 January 2023 to 108,429.

The sum of 108,429 new Ordinary Shares were issued to satisfy the balance of Ordinary Shares arising from the SAYE Exercise.  Admission of the 108,429 new Ordinary Shares has been satisfied by the Company's block listing admitted to the London Stock Exchange on 30 December 2021.

Robin Alfonso, Chief Financial Officer exercised options over 709 Ordinary Shares in the Company.  The balance of the options were exercised by certain other employees and former employees of the Company.

Following his option exercise, Robin Alfonso holds a beneficial interest in 12,151 Ordinary Shares in the Company, representing approximately 0.017 per cent of the total voting rights of the Company, calculated on the same basis.

Following the issue of the new Ordinary Shares, the Company has a total issued share capital of 71,380,400 Ordinary Shares each carrying one voting right. The Company holds no Ordinary Shares in treasury. Therefore, following the issue of the new Ordinary Shares, the total number of voting rights in the Company will be 71,380,400. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

Contacts:

CVS Group plc  via Camarco

Richard Fairman, CEO

Jenny Farrer, Company Secretary

Peel Hunt LLP (Nominated Adviser & Broker)                                               [phone]

Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

   Berenberg (Joint Broker)                                                                                    [phone]

Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

Camarco (Financial PR) 

Geoffrey Pelham-Lane                                                                                      [phone]

Ginny Pulbrook  [phone]

  Toby Strong  [phone]  

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Robin Alfonso
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	CVS Group plc
b)	LEI	213800J41XDQ2NX48O05
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.2 pence each GB00B2863827
b)	Nature of the transaction	Exercise of options under the 2019 SAYE Plan (1 January  2023 maturity)
c)	Price(s) and volume(s)	Price(s) Volume   £8.63 709
d)	Aggregated information - Aggregated volume - Price	N/A - single transaction
e)	Date of the transaction	10 January 2023
f)	Place of the transaction	London Stock Exchange - AIM

 

END

 

 

DSHLBLFFXFLFBBX